c-Met Binding Nucleic Acid Aptamers for Cancer Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective substances to bind and neutralize the c-Met protein, which is overexpressed in various cancers, hindering diagnosis and treatment options.
Innovation Solution
Development of specific c-Met binding nucleic acid molecules, including RNA aptamers, that can bind to c-Met, neutralize its function, and serve as diagnostic and therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to detect and treat c-Met-related diseases, then existing diagnostic and therapeutic options are limited, but effective binding substances to neutralize c-Met are lacking
Solution Approach 1:
The patent uses nucleic acid molecules (aptamers) as intermediary substances that specifically bind to c-Met protein. These aptamers act as mediators between the diagnostic/therapeutic need and the c-Met target, providing both detection capability and neutralization function. The aptamers bind to c-Met with high affinity and specificity, enabling effective neutralization of c-Met signaling pathways while serving as detectable markers for diagnosis.
2Adaptability or versatility
If no specific c-Met binding substance is available, then diagnosis and treatment of c-Met-related diseases are hindered, but developing such substances requires identification of effective binding molecules
Solution Approach 1:
The patent employs aptamer selection methodologies where nucleic acid libraries are subjected to systematic evolution of ligands by exponential enrichment (SELEX) processes. The aptamers self-select and self-optimize their binding affinity and specificity for c-Met through iterative rounds of selection and amplification. This self-service approach enables the identification of high-affinity binding molecules without requiring complex external screening mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These nucleic acid molecules effectively inhibit c-Met function, enabling early diagnosis and treatment of c-Met-related diseases, including cancer, by specifically binding to c-Met and inhibiting its signaling pathways.
Implementation Method 1
a nucleic acid molecule for use in the treatment of a disease in which c-Met is involved... capable of binding to c-Met... neutralizing the action of c-Met
Data Source
AI summary
The present invention provides a nucleic acid molecule capable of binding to c-Met as a substance that can be used for clarification of the pathogenic mechanism of diseases caused by c-Met, diagnosis and treatment of the diseases, and the like, and also the use thereof. The c-Met binding nucleic acid molecule of the present invention is any one of the following nucleic acid molecules (A1), (A2), (B1), and (B2).(A1) a nucleic acid molecule including the base sequence of any one of SEQ ID NOs: 1 to 38(A2) a nucleic acid molecule that is capable of binding to c-Met and includes a base sequence obtained by substitution, deletion, addition, and/or insertion of one or more bases in the base sequence of any one of SEQ ID NOs: 1 to 38(B1) a nucleic acid molecule including the base sequence of any one of SEQ ID NOs: 39 to 76(B2) a nucleic acid molecule that is capable of binding to c-Met and includes a base sequence obtained by substitution, deletion, addition, and/or insertion of one or more bases in the base sequence of any one of SEQ ID NOs: 39 to 76.